

# Kerry Dwan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/917952/publications.pdf>

Version: 2024-02-01

72  
papers

7,014  
citations

159525

30  
h-index

106281

65  
g-index

76  
all docs

76  
docs citations

76  
times ranked

10396  
citing authors

#	ARTICLE	IF	CITATIONS
1	Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias. PLoS ONE, 2008, 3, e3081.	1.1	1,142
2	The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ: British Medical Journal, 2010, 340, c365-c365.	2.4	896
3	Exercise for depression. The Cochrane Library, 2013, 2013, CD004366.	1.5	859
4	Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias " An Updated Review. PLoS ONE, 2013, 8, e66844.	1.1	783
5	CONSORT 2010 statement: extension to randomised crossover trials. BMJ: British Medical Journal, 2019, 366, l4378.	2.4	306
6	Exercise for depression. , 2012, , CD004366.		235
7	Bisphosphonate therapy for osteogenesis imperfecta. The Cochrane Library, 2016, 2016, CD005088.	1.5	173
8	Comparison of protocols and registry entries to published reports for randomised controlled trials. The Cochrane Library, 2011, 2011, MR000031.	1.5	166
9	Bias due to selective inclusion and reporting of outcomes and analyses in systematic reviews of randomised trials of healthcare interventions. The Cochrane Library, 2015, 2015, MR000035.	1.5	152
10	Evidence for the Selective Reporting of Analyses and Discrepancies in Clinical Trials: A Systematic Review of Cohort Studies of Clinical Trials. PLoS Medicine, 2014, 11, e1001666.	3.9	151
11	First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. The Cochrane Library, 2016, , CD010383.	1.5	146
12	Exercise for Depression. JAMA - Journal of the American Medical Association, 2014, 311, 2432.	3.8	143
13	The clinical effectiveness of central venous catheters treated with anti-infective agents in preventing catheter-related bloodstream infections: A systematic review*. Critical Care Medicine, 2009, 37, 702-712.	0.4	133
14	Video calls for reducing social isolation and loneliness in older people: a rapid review. The Cochrane Library, 2020, 2020, CD013632.	1.5	122
15	Bisphosphonate therapy for osteogenesis imperfecta. , 2014, , CD005088.		93
16	Impregnated central venous catheters for prevention of bloodstream infection in children (the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 14)	6.3	89
17	Outcome reporting bias in trials: a methodological approach for assessment and adjustment in systematic reviews. BMJ: British Medical Journal, 2018, 362, k3802.	2.4	83
18	Inhaled antibiotics for long-term therapy in cystic fibrosis. The Cochrane Library, 2011, , CD001021.	1.5	82

#	ARTICLE	IF	CITATIONS
19	Outcome Discrepancies and Selective Reporting: Impacting the Leading Journals?. PLoS ONE, 2015, 10, e0127495.	1.1	61
20	The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation. Health Technology Assessment, 2015, 19, 1-192.	1.3	58
21	Antibiotic-impregnated ventriculoperitoneal shunts—a multi-centre British paediatric neurosurgery group (BPNG) study using historical controls. Child's Nervous System, 2011, 27, 575-581.	0.6	56
22	Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis. The Cochrane Library, 2015, , CD003147.	1.5	55
23	Assessing the potential for outcome reporting bias in a review: a tutorial. Trials, 2010, 11, 52.	0.7	54
24	A third of systematic reviews changed or did not specify the primary outcome: a PROSPERO register study. Journal of Clinical Epidemiology, 2016, 79, 46-54.	2.4	52
25	Comparison of Randomized Controlled Trial Registry Entries and Content of Reports in Surgery Journals. Annals of Surgery, 2013, 257, 1007-1015.	2.1	47
26	Reliability of the revised Cochrane risk-of-bias tool for randomised trials (RoB2) improved with the use of implementation instruction. Journal of Clinical Epidemiology, 2022, 141, 99-105.	2.4	46
27	Deferred Consent for Randomized Controlled Trials in Emergency Care Settings. Pediatrics, 2015, 136, e1316-e1322.	1.0	44
28	Mepolizumab versus placebo for asthma. , 2015, , CD010834.		40
29	Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. , 2013, , CD003146.		39
30	Following the science? Comparison of methodological and reporting quality of covid-19 and other research from the first wave of the pandemic. BMC Medicine, 2021, 19, 46.	2.3	39
31	Sharing Individual Participant Data from Clinical Trials: An Opinion Survey Regarding the Establishment of a Central Repository. PLoS ONE, 2014, 9, e97886.	1.1	38
32	Selective reporting of outcomes in randomised controlled trials in systematic reviews of cystic fibrosis. BMJ Open, 2013, 3, e002709.	0.8	37
33	Inhaled magnesium sulfate in the treatment of acute asthma. The Cochrane Library, 2012, 12, CD003898.	1.5	35
34	The Use and Reporting of the Cross-Over Study Design in Clinical Trials and Systematic Reviews: A Systematic Assessment. PLoS ONE, 2016, 11, e0159014.	1.1	34
35	Reporting of clinical trials: a review of research funders' guidelines. Trials, 2008, 9, 66.	0.7	33
36	Reporting of Adverse Events in Surgical Trials: Critical Appraisal of Current Practice. World Journal of Surgery, 2015, 39, 80-87.	0.8	32

#	ARTICLE	IF	CITATIONS
37	Pharmacological treatment of acute agitation associated with psychotic and bipolar disorder: a systematic review and meta-analysis. <i>Human Psychopharmacology</i> , 2016, 31, 268-285.	0.7	31
38	A systematic review and meta-analysis of Synacthen tests for assessing hypothalamic-pituitary-adrenal insufficiency in children. <i>Archives of Disease in Childhood</i> , 2016, 101, 847-853.	1.0	29
39	A model-based correction for outcome reporting bias in meta-analysis. <i>Biostatistics</i> , 2014, 15, 370-383.	0.9	28
40	Moderators of the effect of psychological interventions on depression and anxiety in cardiac surgery patients: A systematic review and meta-analysis. <i>Behaviour Research and Therapy</i> , 2015, 73, 151-164.	1.6	28
41	Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis. <i>The Cochrane Library</i> , 2015, , CD009841.	1.5	26
42	<i>NAT2</i> variants and toxicity related to anti-tuberculosis agents: a systematic review and meta-analysis. <i>International Journal of Tuberculosis and Lung Disease</i> , 2019, 23, 293-305.	0.6	24
43	The clinical effectiveness and cost-effectiveness of heated humidified high-flow nasal cannula compared with usual care for preterm infants: systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2016, 20, 1-68.	1.3	22
44	Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors. <i>The Cochrane Library</i> , 2020, 2020, CD004449.	1.5	21
45	Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer. <i>Pharmacoeconomics</i> , 2015, 33, 13-23.	1.7	21
46	Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2015, 19, 1-134.	1.3	20
47	Discrepancies in Outcome Reporting Exist Between Protocols and Published Oral Health Cochrane Systematic Reviews. <i>PLoS ONE</i> , 2015, 10, e0137667.	1.1	19
48	Allopurinol for the treatment of chronic kidney disease: asystematic review. <i>Health Technology Assessment</i> , 2014, 18, 1-77, v-vi.	1.3	19
49	CATheter Infections in CHildren (CATCH): a randomised controlled trial and economic evaluation comparing impregnated and standard central venous catheters in children. <i>Health Technology Assessment</i> , 2016, 20, 1-220.	1.3	19
50	Risk of Bias 2 in Cochrane Reviews: a phased approach for the introduction of new methodology. <i>The Cochrane Library</i> , 2020, 10, ED000148.	1.5	17
51	STrengthening the Reporting Of Pharmacogenetic Studies: Development of the STROPS guideline. <i>PLoS Medicine</i> , 2020, 17, e1003344.	3.9	17
52	Vilanterol and fluticasone furoate for asthma. <i>The Cochrane Library</i> , 2016, 9, CD010758.	1.5	11
53	Influence of genetic variants on toxicity to anti-tubercular agents: a systematic review and meta-analysis (protocol). <i>Systematic Reviews</i> , 2017, 6, 142.	2.5	11
54	Feasibility study to examine discrepancy rates in prespecified and reported outcomes in articles submitted to<i>The BMJ</i>. <i>BMJ Open</i> , 2016, 6, e010075.	0.8	10

#	ARTICLE	IF	CITATIONS
55	CYP genetic variants and toxicity related to anti-tubercular agents: a systematic review and meta-analysis. <i>Systematic Reviews</i> , 2018, 7, 204.	2.5	10
56	The Use of Systematic Reviews When Designing and Reporting Surgical Trials. <i>Annals of Surgery</i> , 2017, 265, e35-e36.	2.1	9
57	How Much Participant Outcome Data Is Missing from Sight: Findings from a Cohort of Trials Submitted to a German Research Ethics Committee. <i>PLoS ONE</i> , 2016, 11, e0157883.	1.1	8
58	Comparison of protocols and registry entries to published reports for randomised controlled trials. <i>Journal of Evidence-Based Medicine</i> , 2011, 4, 194-194.	0.7	7
59	Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective. <i>Pharmacoeconomics</i> , 2015, 33, 893-904.	1.7	7
60	Methodological review showed correct absolute effect size estimates for time-to-event outcomes in less than one-third of cancer-related systematic reviews. <i>Journal of Clinical Epidemiology</i> , 2019, 108, 1-9.	2.4	6
61	Do systematic reviews still exclude studies with "no relevant outcome data"? <i>BMJ: British Medical Journal</i> , 2017, 358, j3919.	2.4	5
62	Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis. <i>Health Technology Assessment</i> , 2015, 19, 1-130.	1.3	5
63	Reporting of Cochrane systematic review protocols with network meta-analyses: A scoping review. <i>Research Synthesis Methods</i> , 2022, 13, 164-175.	4.2	5
64	Transcranial Doppler Screening in a Regional Care Network for Sickle Cell Disease in the United Kingdom. <i>Journal of Pediatric Hematology/Oncology</i> , 2016, 38, 517-524.	0.3	4
65	Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis. <i>The Cochrane Library</i> , 0, .	1.5	3
66	A cross-sectional audit showed that most Cochrane intervention reviews searched trial registers. <i>Journal of Clinical Epidemiology</i> , 2019, 113, 86-91.	2.4	3
67	Exercise to Combat Depression: Reply. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 2167.	3.8	2
68	Selective reporting in clinical trials - an examination of discrepancy rates in pre-specified and reported outcomes in articles submitted to the BMJ. <i>Trials</i> , 2015, 16, .	0.7	2
69	Development of a checklist to detect errors in meta-analyses in systematic reviews of interventions: study protocol. <i>F1000Research</i> , 2021, 10, 455.	0.8	2
70	Advocating for evidence-informed decisions to make healthcare fit for each person. <i>BMJ Evidence-Based Medicine</i> , 2022, 27, 65-66.	1.7	2
71	Potentiators for cystic fibrosis "targeting the underlying molecular defect. <i>Paediatric Respiratory Reviews</i> , 2015, 16, 162-164.	1.2	0
72	Subcutaneous omalizumab for people with asthma. <i>The Cochrane Library</i> , 2021, 2021, .	1.5	0